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jsk@dadlnet.dkAbstractThe antihypertensive actions of glucagon-like peptide-1 (GLP1) receptor agonists have been
linked to the release of atrial natriuretic peptide (ANP) in mice. Whether a GLP1–ANP axis
exists in humans is unknown. In this study, we examined 12 healthy young males in a
randomized, controlled, double-blinded, single-day, cross-over study to evaluate the effects
of a 2-h native GLP1 infusion. Plasma proANP concentrations were measured by an
automated mid-region-directed proANP immunoassay and N-terminal pro B-type natriuretic
peptide (BNP) on Roche Modular E170. Urine was collected for measurements of sodium
excretion. Although GLP1 infusion increased the urinary sodium excretion markedly, there
were no significant changes in either proANP or proBNP concentrations. When GLP1 infusion
was stopped, sodium excretion declined rapidly. As proANP concentration reflects ANP
secretion, our data could not confirm the existence of a GLP1–ANP axis in humans. Especially,
the natriuretic effects of GLP1 seem unlikely to be mediated exclusively via ANP.Key Words
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.0 UEndocrine Connections
(2014) 3, 11–16IntroductionGlucagon-like peptide-1 (GLP1) is a gut-derived incretin
hormone with multiple actions in addition to control of
glucose homeostasis (1). Synthetic GLP1 receptor (GLP1R)
agonists lower blood pressure in patients with type 2
diabetes through mechanisms not fully comprehended (2).
The antihypertensive effects seem non-acute in nature (3)
but sets in before substantial weight loss (4). GLP1
has natriuretic effects in humans (5, 6) and some studies
suggest that GLP1 has vasorelaxant effects (7).A recently published article by Kim et al. (8) reports
that atrial natriuretic peptide (ANP) mediates the anti-
hypertensive effects of GLP1 in mice. The authors
convincingly demonstrate that GLP1R activation stimu-
lates ANP release from atrial cardiomyocytes and that
GLP1 exclusively acts via ANP to induce vasodilatation
and natriuresis (8). The findings, therefore, define a novel
GLP1–ANP axis and expand our view on GLP1-induced
cardiovascular and renal actions.sed under a Creative Commons
nported License.
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Research J Skov et al. GLP1–ANP axis in humans? 2–6 3 :12To explore whether this GLP1–ANP axis exists in
humans, we measured plasma proANP concentrations
in healthy males exposed to a natriuresis inducing native
GLP1 infusion.Subjects and methods
Design
The study was performed using a randomized, double-
blinded, placebo-controlled, single-day cross-over design.
Subjects
Twelve healthy male subjects were studied. Mean age was
23.4G3.1 years (S.D.) and mean BMI was 23.0G2.0 kg/m2
(S.D.). Each volunteer provided written informed consent.
The protocol was approved by the local Human Ethics
Research Committee and carried out in accordance with
the Helsinki Declaration.
All volunteers had a normal physical examination
as well as normal blood and urine screenings. None were
on medication or had any history of critical medical
conditions. Fourteen subjects were screened, one with-
drew after screening and one was excluded after the study
because of fluid retention due to impaired urinations.Protocol
The primary study objective was to investigate GLP1-
induced effects on kidney function and the procedures
and results regarding this part have been previously
described (6). In summary, the protocol involved blood
sampling, infusions of radioactive isotopes, and a prior
ingestion of small doses lithium.
Volunteers arrived at the clinic at 0715 h after an over-
night fast. They were placed in bed where they stayed supine
during the study day. Catheters were placed in each ante-
cubital vein, one for blood sampling, the other for infusion.
At w0730 h, an isotonic 0.9% saline infusion was
started at a rate of 750 ml/h and continued throughout
the study to stimulate urine production. At 0900 h a 2-h
infusion of either GLP1, dissolved in 0.9% saline
containing 1% human albumin, or the solvent alone
(placebo) was initiated. This was followed by a 2-h
washout period before infusion of the placebo and GLP1
solutions for the next 2 h. The GLP1 infusion rate was
1.25 pmol/kg per min.
The two solutions were prepared by the physician in
charge and afterwards blinded to both physician andhttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0087
 2014 The authors
Published by Bioscientifica Ltdvolunteers allowing for the double-blinded study design.
Blood samples were drawn every 20 min, resulting in a
total collection ofw300 ml blood during the entire study
day. Urine was collected every 20 min by voiding in a
bottle. Blood pressure and heart rate (HR) were measured
every 20 min throughout the day.Materials
Synthetic human GLP1(7–36) amide was obtained from
Bachem (Weil am Rhein, Germany).
Assays
GLP1 plasma concentrations were measured by a RIA
method as described earlier (6). For measurement of
plasma proANP, we used an automated proANP immuno-
assay (BRAHMS, Hennigsdorf, Germany) with targeted
epitopes in the mid-region (MR) of the precursor (9).
Unlike ANP, MR-proANP is well preserved in plasma (10).
The intra-assay coefficient of variation (CV) from the
manufacturer is !2.5% in the relevant molar range (20–
1000 pmol/l); the limit of detection is 2.1 pmol/l, and the
limit of quantitation is listed as being 4.5 pmol/l. In our
laboratory, the working interassay CV in the current molar
range was !2% (nZ60). The MR-proANP assay has also
been compared with an in-house gold standard proANP
assay, with excellent correlation in the low range (11).
N-terminal pro B-type natriuretic peptide (BNP) was
measured on Roche Modular E170 using a previously
well-described method (12). The limit of detection was
0.6 pmol/l and values below this limit were set to
0.5 pmol/l. Urinary sodium concentration was measured
by the accredited laboratory of Aarhus University Hospital.Statistical analysis
A mixed model of repeated measures ANOVA was applied
(subject and subject!period as random variables; group,
time, and group!time as fixed variables). The P value of
the interaction group!time is reported throughout. The
proBNP data were logarithmically transformed before
analyses. A P!0.05 is considered statistically significant.
STATA, version 11.1 (StataCorp., College Station, TX, USA)
was used for calculations.Results
When infusion of native GLP1 1.25 pmol/kg per min
started, the baseline GLP1 concentration increased nearlyThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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Research J Skov et al. GLP1–ANP axis in humans? 3–6 3 :13tenfold and remained elevated until the infusion was
terminated (P!0.001). The urinary sodium excretion
increased w40% (P!0.001) during GLP1 infusion but
rapidly returned toward baseline when infusion stopped
(as shown for the group randomized to GLP1 in the
first intervention period, nZ6). GLP1 infusion did not
affect proANP plasma concentration (PZ0.32; see Fig. 1).
Both proANP and proBNP concentrations increased
slightly over time independent of the order of GLP1 and
placebo infusions.
There was no acute impact on either systolic blood
pressure (SBP; PZ0.31) or diastolic blood pressure (DBP;
PZ0.63), but HR transiently increased by approximately
six beats per minute (PZ0.01). The effect on vital
parameters has previously been published (6) (see Fig. 2).A B
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Figure 1
GLP1 infusion increased plasma GLP1 concentration nearly tenfold, (A) but
this had no significant effect on plasma proANP (B) or proBNP (C)
concentrations despite a marked increase in urinary sodium excretion (D).
Sodium excretion rapidly declined when GLP1 infusion stopped (E).
Open circles represent values from the placebo period; closed circles
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We have shown that an almost tenfold increase in
GLP1 concentration, which markedly induced natriuresis,
was incapable of increasing plasma proANP or proBNP
concentrations in healthy males. As proANP concen-
tration reflects ANP secretion, the result questions the
existence of a functional GLP1–ANP axis in humans.
Especially the natriuretic effect seems unlikely to be
mediated exclusively via ANP.GLP1 does not increase proANP concentration
Despite a robust and sustained increase in GLP1 concen-
trations during the 2-h GLP1 intervention, we were unable
to detect an increase in proANP plasma concentration.C
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This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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Figure 2
GLP1 infusion had no acute effect on either SBP (A) or DBP (B) but there
was a transient increase in heart rate (C). Open circles represent values
from the placebo period and closed circles from the GLP1 period.
Statistical significance was determined by ANOVA. Data are shown as mean
and error bars represent S.E.M.
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Research J Skov et al. GLP1–ANP axis in humans? 4–6 3 :14Plasma proANP is today used clinically as a surrogate
marker for cardiac ANP secretion. The prohormone has a
longer half-life in the circulation, shows smaller fluctu-
ations, and the peptide is better preserved in plasma
samples (10).
The half-life of ANP is !5 min, and while the exact
half-life of proANP is unknown, we have seen 50%
reduction of the proANP concentration in vivo within
60 min (13). This should facilitate our ability to detect a
rise in the secretion of ANP (with its synchronous and
equimolar secretion of proANP).
In the article by Kim et al. (8), the majority of their
numerous experiments were performed with the GLP1R
agonist liraglutide. However, by using GLP1R knockout
mice, they showed that ANP release indeed depended on
GLP1R activations; in addition, exendin-4, native GLP1,
as well as a meal (endogenous GLP1) were capable of
increasing ANP concentrations.
We would therefore expect native GLP1 to stimulate
ANP secretion in humans if the same mechanisms
were present. As GLP1 failed to increase proANP levels,
we conclude that either the GLP1–ANP axis is solely a
mouse phenomenon or that a GLP1 induced release of
ANP in humans must be minor or very transient.
A recent paper exploring the effect of ameal on plasma
proANP concentrations in humans (13) also speaks against
a major effect of GLP1 on ANP secretion. Six overnight
fasted healthy young individuals were given a standar-
dized meal and proANP was measured repeatedly for the
first three postprandial hours. The meal was found tohttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0087
 2014 The authors
Published by Bioscientifica Ltdsignificantly reduce proANP concentrations. Since a meal
is the physiological stimulus for GLP1 secretion we would
expect the meal to increase proANP if a GLP1–ANP axis
existed in humans.No effect of GLP1 on proBNP
We also measured N-terminal-proBNP as a marker of BNP
secretion, but found no effect in response to GLP1
infusion. Kim et al. (8) did not either find BNP to be a
mediator of GLP1-actions in mice. It seems therefore
reasonable to conclude that BNP is not part of an
important gut–heart axis.ANP is not exclusively mediating GLP1’s natriuretic actions
We found infusion of native GLP1 to increase the urinary
sodium excretion markedly in humans (Fig. 1D). Further,
the increase in natriuresis was sustained during the entire
period of GLP1 infusion, but rapidly returned toward
baseline when infusion was stopped (Fig. 1E). As there
were no changes in proANP concentrations, the finding is
inconsistent with ANP being an essential mediator of
GLP1’s natriuretic actions in humans.
Kim et al. (8) found liraglutide to markedly increase
natriuresis in mice and thereby confirmed an earlier
finding of liraglutide-induced diuresis in rats (14).
Liraglutide had no effect on natriuresis in ANP knockout
mice, indicating that ANP is required for the natriuretic
actions of GLP1R agonists (8). The different GLP1RThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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Research J Skov et al. GLP1–ANP axis in humans? 5–6 3 :15agonists often induced an initial peak in ANP level, which
disappeared within the first hour (8). This was especially
the case during the light-on periods. We found the
increased urinary sodium excretion to be sustained
under the GLP1 infusion and hereafter to decrease rapidly.
Therefore, it is unlikely that the effect was caused by a
hypothetical initial ANP peak not reflected by increases in
proANP concentrations.
There may, however, be important differences
between native GLP1 and liraglutide with respect to
renal actions. The natriuretic effect has been hypothesized
to depend on activation of GLP1Rs located in the proximal
tubules (15). While GLP1 is freely filtered and partly
cleared in the kidneys, only minimal amounts of
liraglutide pass the glomerular filtration barrier (16). If
GLP1R activation depends on GLP1R agonists located in
the tubular lumen, liraglutide may not be functioning.
Though liraglutide induces natriuresis in rodents (8, 14),
to our knowledge, it has never been reported whether
liraglutide actually has natriuretic properties in humans.
ANP infusion markedly increases glomerular filtration
rate in rodents (17, 18) and humans (19, 20). GLP1
infusion also strikingly increases glomerular filtration rate
in rodents (15, 21) but interestingly not in humans (5, 6).
This difference could be explained by a GLP1–ANP axis
which is only functional in rodents.No acute effect of GLP1 on blood pressure
We did not find native GLP1 infusion to acutely affect
blood pressure in healthy males (Fig. 2), which we have
also prior reported (6). Kim et al. (8) found different GLP1R
agonists to reduce blood pressure but only in mice which
were hypertensive secondary to an angiotensin II infusion
or to transaortic constriction, and the effects were most
pronounced during the light-off periods. Our findings,
therefore, are not in contrast, because the volunteers were
normotensive. Further, the results are also in line with
other human studies showing no acute effect of GLP1R
agonists on blood pressure (3). A GLP1-induced increase
in HR (Fig. 2C) has been reported in both rodents and
humans, although usually not reported to be transient.
Notably, Kim et al. (8) found that the positive chrono-
tropic effect of GLP1R agonists was independent of ANP.Implications for proANP as a biomarker of heart failure
Mid-regional proANP has been introduced as a heart
failure biomarker (22). Kim et al. (8) found GLP1R agonists
to markedly increase ANP levels in mice but found nohttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0087
 2014 The authors
Published by Bioscientifica Ltdeffect on BNP. This indirectly raises the question whether
proANP is a valid biomarker of heart failure in patients
treated with GLP1-based products or if derives of BNP are
better biomarkers in these cases. Diabetes per se is known
to increase the risk of heart failure, and rising numbers
of patients are now treated with GLP1 products which
make the concern for false positive results highly relevant.
Our data showed no impact on proANP or proBNP
after GLP1 infusion. Consequently, we have no reason to
believe that either proANP or proBNP are inadequate
biomarkers of heart failure in patients treated with GLP1-
based products. The question, however, demands further
investigations in type 2 diabetes patients treated with
GLP1R agonists for longer periods.
The major limitation of this study is that it was
not originally designed to evaluate a GLP1–ANP axis and
the proANP analyses were performed post-hoc. Further, we
did notmeasure ANP itself because our blood samples were
not properly pretreated to allow for acceptable analyses
of this highly unstable peptide. High saline infusion
rates and frequent blood sampling may have induced
period effects.
In conclusion, our data cannot confirm the existence
of a GLP1–ANP axis in humans and we find especially
GLP1’s natriuretic effect unlikely to be caused exclusively
via increased ANP secretion. The topic is important
because increasing numbers of patients are treated with
GLP1-based products which make cardiovascular side
effects an obvious topic of interest. Dedicated studies
are needed to further explore the GLP1–ANP relationship
in humans.Declaration of interest
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